Clinical utility of T cell engagers (TCEs) in cancer immunotherapy for solid tumors is hampered by on-target off-tumor activity and dose-limiting adverse events. A study now proposes a solution to tackle these challenges through the design and preclinical characterization of extended half-life TCEs that are conditionally activated in the tumor microenvironment.
References
Arvedson, T. et al. Annu. Rev. Cancer Biol. 6, 17–34 (2022).
Goebeler, M.-E. & Bargou, R. C. Nat. Rev. Clin. Oncol. 17, 418–434 (2020).
Vafa, O. & Trinklein, N. D. Front. Oncol. 10, 446 (2020).
Baeuerle, P. A. & Wesche, H. Curr. Opin. Oncol. 34, 552–558 (2022).
Cattaruzza, F. et al. Nat. Cancer https://doi.org/10.1038/s43018-023-00536-9 (2023).
Dudani, J. S., Warren, A. D. & Bhatia, S. N. Annu. Rev. Cancer Biol. 2, 353–376 (2018).
Schellenberger, V. et al. Nat. Biotechnol. 27, 1186–1190 (2009).
Podust, V. N. et al. J. Control Release 240, 52–66 (2016).
Yuen, K. C. J. et al. J. Clin. Endocrinol. Metab. 98, 2595–2603 (2013).
Oldenburg, J. et al. Res. Pract. Thromb. Haemost. 5 (Suppl. 2), Abstract PB0538 (2021).
Jenkins, R. W., Barbie, D. A. & Flaherty, K. T. Br. J. Cancer 118, 9–16 (2018).
Kobold, S. et al. Front Oncol 8, 285 (2018).
Saber, H. et al. Toxicol. Pharmacol. 90, 144–152 (2017).
Zhou, Y. et al. J. Immunother. Cancer 10, e004225 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Silver, A.B., Wang, J. & Spangler, J.B. Masking T cell engagers mitigates on-target off-tumor activity. Nat Cancer 4, 439–441 (2023). https://doi.org/10.1038/s43018-023-00529-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-023-00529-8
- Springer Nature America, Inc.